Sfoglia per AUTORE
CAVO A
Collezione AO Ordine Mauriziano

  

Items : 11

Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study). in Future oncology (London, England) / Future Oncol. 2024 May 3:1-19. doi: 10.1080/14796694.2024.2340960.

2024
AO Ordine Mauriziano

Buti S; Galli L; Fornarini G; Llaja Obispo MA; Banna GL; Maffezzoli M; Cremante M; Damassi A; Murianni V; Sbaraglia M; Catalano F; Brunelli M; Signori A; Milella M; Dei Tos AP; Bimbatti D; Cavo A; Vignani F; Merler S; Maruzzo M; Gaggero G; Vellone VG; Galuppini F; Spada M; Masini C; Rescigno P; Rebuzzi SE;

Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2024 Jun;22(3):102074. doi: 10.1016/j.clgc.2024.102074. Epub 2024 Mar 18.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Buti S; Formisano L; Prati V; Bassanelli M; Cavo A; Mattana A; Pierantoni F; Di Napoli M; Mennitto A; Marchetti A; Grillone F; Caffo O; Vignani F; Roviello G; Calabrò F; Ermacora P; Maiorano BA; Vitale MG; Iacovelli R; Bimbatti D; Claps M; Massari F; Giudice GC; Maruzzo M; Mollica V;

Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2024 Jul 2;73(9):161. doi: 10.1007/s00262-024-03741-2.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Rescigno P; Fornarini G; Buti S; Rebuzzi SE; Vignani F; Cavo A; Signori A; Banna GL; Tudini M; Malgeri A; Nole F; Prati G; Morelli F; Messina M; Di Napoli M; Atzori F; Prati V; Soraru M; Panni S; Mollica V; Pipitone S; Ricotta R; Fratino L; Catalano F; Milella M; Procopio G; Naglieri E; Masini C; Zucal PA; et alii...

Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab. in Immunotherapy / Immunotherapy. 2024 Aug 19:1-9. doi: 10.1080/1750743X.2024.2385881.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Murianni V; Rescigno P; Banna GL; Fornarini G; Buti S; Nolè F; Catalano F; Prati G; Morelli F; Messina M; Atzori F; Tudini M; Prati V; Cavo A; Roviello G; Vignani F; Caffo O; Napoli MD; Malgeri A; Rebuzzi SE; Signori A; Damassi A; Cremante M;

Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study. in Frontiers in oncology / Front Oncol. 2024 Feb 12;14:1307635. doi: 10.3389/fonc.2024.1307635. eCollection 2024.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Chiellino S; Galli L; Banna GL; Fornarini G; Rescigno P; Cremante M; Damassi A; Catalano F; Roviello G; Cavo A; Lipari H; Vignani F; Prati G; Spada M; Nolè F; Morelli F; Di Napoli M; Caffo O; Malgeri A; Atzori F; Prati V; Tudini M; Sorarù M; Mollica V; Ricotta R; Baldessari C; Procopio G; Milella M; Fratino L; et alii...

Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study). in Future oncology (London, England) / Future Oncol. 2024;20(21):1495-1503. doi: 10.2217/fon-2023-1068. Epub 2024 Jun 12.

2024
AO Ordine Mauriziano

Fornarini G; Rebuzzi SE; Llaja Obispo MA; Banna GL; Maffezzoli M; Cremante M; Damassi A; Murianni V; Sbaraglia M; Dei Tos AP; Catalano F; Brunelli M; Signori A; Milella M; Bimbatti D; Cavo A; Vignani F; Merler S; Maruzzo M; Vellone VG; Gaggero G; Galuppini F; Masini C; Spada M; Galli L; Buti S; Rescigno P;

Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab. in JAMA network open / JAMA Netw Open. 2023 Nov 1;6(11):e2345185. doi: 10.1001/jamanetworkopen.2023.45185.

2023
ASL Cuneo 2
AO Ordine Mauriziano

Naglieri E; Signori A; Banna GL; Rescigno P; Antonuzzo L; Roviello G; Di Napoli M; Malgeri A; Cavo A; Vignani F; Nolè F; Prati G; Atzori F; Morelli F; Caffo O; Prati V; Mollica V; Tudini M; Fratino L; Sorarù M; Ricotta R; Pipitone S; Catalano F; Chiellino S; Milella M; Procopio G; Fornarini G; Zucali PA; Buti S; et alii...

Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study. in Cancers / Cancers (Basel). 2023 Apr 21;15(8):2394. doi: 10.3390/cancers15082394.

2023
AO Ordine Mauriziano

Fornarini G; Buti S; Banna GL; Maffezzoli M; Cremante M; Llaja Obispo MA; Murianni V; Dei Tos AP; Sbaraglia M; Mencoboni M; Panepinto O; Milella M; Basso U; Cavo A; Merler S; Vignani F; Maruzzo M; Rescigno P; Damassi A; Gaggero G; Signori A; Catalano F; Vellone VG; Galuppini F; Brunelli M; Rebuzzi SE;

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study. in Journal of translational medicine / J Transl Med. 2022 Sep 30;20(1):435. doi: 10.1186/s12967-022-03601-6.

2022
ASL Cuneo 2
AO Ordine Mauriziano

Roviello G; Rescigno P; Cavo A; Atzori F; Di Napoli M; Caffo O; Messina M; Morelli F; Prati G; Nolè F; Vignani F; Santini D; Cortellini A; Prati V; Soto Parra HJ; Mollica V; Sorarù M; Santoni M; Panni S; Ricotta R; Pipitone S; Fratino L; Buti S; Procopio G; Milella M; Boccardo F; Fantinel E; Naglieri E; Galli L; et alii...

The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The ?-Meet-URO analysis. in Frontiers in oncology / Front Oncol. 2022 Sep 23;12:955501. doi: 10.3389/fonc.2022.955501. eCollection 2022.

2022
ASL Cuneo 2
AO Ordine Mauriziano

Buti S; Fornarini G; Banna GL; Porta C; Llaja Obispo MA; Roviello G; Cavo A; Vignani F; Nolè F; Caffo O; Messina M; Morelli F; Prati G; Soto Parra HJ; Atzori F; Di Napoli M; Santoni M; Cortellini A; Prati V; Massari F; Sorarù M; Panni S; Fratino L; Sabbatini R; Ricotta R; Boccardo F; Milella M; Procopio G; Zucali PA; et alii...

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). in Therapeutic advances in medical oncology / Ther Adv Med Oncol. 2021 May 18;13:17588359211019642. doi: 10.1177/17588359211019642. eCollection 20

2021
AO Ordine Mauriziano
ASL Cuneo 2

Buti S; Porta C; Perrino M; Brunelli M; Iacovelli R; Paolieri F; Chiellino S; Bersanelli M; Casadei C; Cavo A; Roviello G; Pierantoni F; Prati G; Vignani F; Nolè F; Morelli F; Messina M; Pignata S; Messina C; Stellato M; Atzori F; Soto Parra HJ; Cortellini A; Prati V; Sorarù M; Santoni M; Mollica V; Panni S; Fratino L; et alii...